Replimune’s Pivotal Year: All Eyes on 2026 FDA Decision

For Replimune and its investors, 2026 is shaping up to be a defining period. After a significant regulatory setback in mid-2025, the company’s prospects are now revitalized, centered on a crucial upcoming decision from the U.S. Food and Drug Administration. The potential approval of its lead candidate, RP1 for advanced melanoma, alongside compelling new clinical data, could mark a dramatic turnaround for the biotech firm.

Regulatory Pathway Clears

A major positive development occurred on October 20, 2025, when the FDA accepted the company’s resubmitted Biologics License Application (BLA) for RP1. This action represents a critical reversal of fortune following a Complete Response Letter the agency issued in July of the same year. The regulator has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 10, 2026, finally providing shareholders with a clear timeline for a potential commercial launch after months of uncertainty.

This regulatory progress helps to counterbalance the negative sentiment that followed the initial rejection, which had triggered a steep share price decline and prompted investor lawsuits alleging the company had overpromised on its chances for success.

Compelling Clinical Evidence Emerges

Adding substantial weight to the case for approval, Replimune released new biomarker data on November 11, 2025. The analysis demonstrates that RP1, used in combination with nivolumab, can reverse multiple resistance mechanisms to PD-1 blockade in patients with advanced melanoma who had previously failed anti-PD-1 therapy.

Should investors sell immediately? Or is it worth buying Replimune?

This scientific validation highlights the therapy’s potential in a patient population historically considered difficult to treat, potentially carving out a significant competitive advantage for Replimune in the oncology market.

Financial Health Under Scrutiny

Alongside these clinical and regulatory updates, the company reported its financial results for the second quarter of its 2026 fiscal year on November 6, 2025. While specific revenue figures may be less relevant at this pre-commercial stage, market watchers are closely monitoring the company’s cash burn and financial runway. The substantial expenditures required to prepare for a potential April 2026 launch make the company’s financial stability a key consideration for investors.

Key Upcoming Milestones:

• April 10, 2026: FDA decision deadline (PDUFA date) for RP1
• October 20, 2025: FDA accepts resubmitted application for RP1
• November 11, 2025: Promising biomarker data presented
• November 6, 2025: Q2 FY2026 financial results released

The FDA’s acceptance of the application has injected fresh momentum into Replimune’s stock, helping to mitigate the pessimism that followed the July setback. However, the ultimate test still lies ahead. The biotech community is now focused on a single question: will April 2026 finally bring the long-awaited green light for RP1, or will it deliver another disappointing blow?